Literature DB >> 10898436

Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload.

S R Kapadia1, K Yakoob, S Nader, J D Thomas, D L Mann, B P Griffin.   

Abstract

OBJECTIVES: We sought to determine whether serum tumor necrosis factor-alpha (TNF-alpha) levels are elevated in patients with hemodynamically significant pressure and volume overload.
BACKGROUND: It has been previously shown that TNF-alpha messenger ribonucleic acid (mRNA) and protein are rapidly expressed in the hearts of animal models subjected to abrupt hemodynamic overloading. The clinical significance of these experimental findings has not been tested in pathophysiologically relevant clinical models in human subjects.
METHODS: We prospectively measured serum TNF-alpha levels and serum TNF receptor 1 and 2 levels in 21 patients with severe aortic stenosis (AS), in 26 patients with 3+ to 4+ mitral regurgitation (MR) and in normal age- and gender-matched control subjects. Patients with AS and MR were either in New York Heart Association (NYHA) functional class I or II and had no significant coronary disease. We compared the cytokine levels among the groups using analysis of variance. We related cytokine levels to the severity of AS using simple regression analysis.
RESULTS: Serum TNF-alpha levels in patients with AS (2.1 +/- 1.6 pg/ml, n = 21) and MR (1.3 +/-0.7 pg/ml, n = 26) were significantly higher than those in the control subjects (0.7 +/-0.2 pg/ml, n = 28). Serum TNF receptor 1 and 2 levels were also higher in patients with AS and MR than in control subjects. Cytokine levels were higher in patients in NYHA class II than in those in class I. In patients with a normal ejection fraction (>50%, n = 16), there was a mild positive correlation (r = 0.56, p = 0.025) between serum TNF-alpha levels and the mean gradient across the aortic valve.
CONCLUSIONS: This study demonstrates that serum TNF-alpha is elevated in patients with chronic hemodynamic overloading and early cardiac decompensation. Furthermore, these findings suggest not only that peripheral TNF-alpha levels correlate with the severity of the hemodynamic pressure overload, but also that peripheral TNF-alpha and TNF receptor levels increase in direct relation to deteriorating NYHA functional class.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2000        PMID: 10898436     DOI: 10.1016/s0735-1097(00)00721-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

1.  Tumor necrosis factor-α confers cardioprotection through ectopic expression of keratins K8 and K18.

Authors:  Stamatis Papathanasiou; Steffen Rickelt; Maria Eugenia Soriano; Tobias G Schips; Harald J Maier; Constantinos H Davos; Aimilia Varela; Loukas Kaklamanis; Douglas L Mann; Yassemi Capetanaki
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

2.  Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty.

Authors:  Kumral Ergun Cagli; Dursun Aras; Serkan Topaloglu; Bilal Geyik; Selime Ayaz; Goksel Cagirci; Halil Lutfi Kisacik; Sule Korkmaz
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

3.  Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis.

Authors:  Isabelle Amigues; Aylin Tugcu; Cesare Russo; Jon T Giles; Rachelle Morgenstein; Afshin Zartoshti; Christian Schulze; Raul Flores; Sabahat Bokhari; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2019-02-28       Impact factor: 10.995

4.  Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant.

Authors:  Melana Yuzefpolskaya; Bruno Bohn; Mojdeh Nasiri; Amelia M Zuver; Drew D Onat; Eugene A Royzman; Joseph Nwokocha; Melissa Mabasa; Alberto Pinsino; Danielle Brunjes; Antonia Gaudig; Autumn Clemons; Pauline Trinh; Stephania Stump; Marla J Giddins; Veli K Topkara; A Reshad Garan; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Maryjane A Farr; Renu Nandakumar; Anne-Catrin Uhlemann; Paolo C Colombo; Ryan T Demmer
Journal:  J Heart Lung Transplant       Date:  2020-02-13       Impact factor: 10.247

Review 5.  Skeletal muscle inflammation and atrophy in heart failure.

Authors:  Kory J Lavine; Oscar L Sierra
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

6.  Prevalence and implications of diastolic dysfunction after subarachnoid hemorrhage.

Authors:  Alexander Kopelnik; Landis Fisher; Jacob C Miss; Nader Banki; Poyee Tung; Michael T Lawton; Nerissa Ko; Wade S Smith; Barbara Drew; Elyse Foster; Jonathan Zaroff
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

7.  Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy.

Authors:  M Vanderheyden; W J Paulus; M Voss; P Knuefermann; N Sivasubramanian; D Mann; G Baumgarten
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

8.  Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.

Authors:  Meghna D Patel; Jayaram Mohan; Caralin Schneider; Geetika Bajpai; Enkhsaikhan Purevjav; Charles E Canter; Jeffrey Towbin; Andrea Bredemeyer; Kory J Lavine
Journal:  JCI Insight       Date:  2017-07-20

9.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

10.  Adiponectin downregulation is associated with volume overload-induced myocyte dysfunction in rats.

Authors:  Li-li Wang; Dori Miller; Desiree Wanders; Gayani Nanayakkara; Rajesh Amin; Robert Judd; Edward E Morrison; Ju-ming Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.